Our top pick for
Trillium Therapeutics Inc is a biotechnology business based in the US. Trillium Therapeutics shares (TRIL) are listed on the NASDAQ and all prices are listed in US Dollars.
|52-week range||$2.50 - $20.96|
|50-day moving average||$12.45|
|200-day moving average||$13.58|
|Wall St. target price||$11.02|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.55|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$124,000|
|Return on assets TTM||-19.01%|
|Return on equity TTM||-189.45%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
There are currently 8.2 million Trillium Therapeutics shares held short by investors – that's known as Trillium Therapeutics's "short interest". This figure is 7.7% down from 8.9 million last month.
There are a few different ways that this level of interest in shorting Trillium Therapeutics shares can be evaluated.
Trillium Therapeutics's "short interest ratio" (SIR) is the quantity of Trillium Therapeutics shares currently shorted divided by the average quantity of Trillium Therapeutics shares traded daily (recently around 1.5 million). Trillium Therapeutics's SIR currently stands at 5.52. In other words for every 100,000 Trillium Therapeutics shares traded daily on the market, roughly 5520 shares are currently held short.
However Trillium Therapeutics's short interest can also be evaluated against the total number of Trillium Therapeutics shares, or, against the total number of tradable Trillium Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trillium Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Trillium Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0835% of the tradable shares (for every 100,000 tradable Trillium Therapeutics shares, roughly 84 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Trillium Therapeutics.
Find out more about how you can short Trillium Therapeutics stock.
We're not expecting Trillium Therapeutics to pay a dividend over the next 12 months.
Trillium Therapeutics's shares were split on a 1:30 basis on 19 November 2014. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trillium Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Trillium Therapeutics shares which in turn could have impacted Trillium Therapeutics's share price.
Over the last 12 months, Trillium Therapeutics's shares have ranged in value from as little as $2.5 up to $20.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trillium Therapeutics's is 1.9575. This would suggest that Trillium Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Trillium Therapeutics Inc. , a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.